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Abstract
Background: Ventilator-associated respiratory infections (tracheobronchitis, pneumonia) contribute
significant morbidity and mortality to adults receiving care in intensive care units (ICU). Administration
of broad-spectrum intravenous antibiotics, the current standard of care, may have systemic adverse effects.
The efficacy of aerosolized antibiotics for treatment of ventilator-associated respiratory infections remains
unclear. Our objective was to conduct a systematic review of the efficacy of aerosolized antibiotics in the
treatment of ventilator-associated pneumonia (VAP) and tracheobronchitis (VAT), using the Cochrane
Collaboration guidelines.
Methods: We conducted a search of three databases (PubMed, Web of Knowledge and the Cochrane
Collaboration) for randomized, controlled trials studying the use of nebulized antibiotics in VAP and
VAT that measured clinical cure (e.g., change in Clinical Pulmonary Infection Score) as an outcome
measurement. We augmented the electronic searches with hand searches of the references for any
narrative review articles as well as any article included in the systematic review. Included studies were
examined for risk of bias using the Cochrane Handbook’s “Risk of Bias” assessment tool.
Results: Six studies met full inclusion criteria. For the systemic review’s primary outcome (clinical cure),
two studies found clinically and statistically significant improvements in measures of VAP cure while four
found no statistically significant difference in measurements of cure. No studies found inferiority of
aerosolized antibiotics. The included studies had various degrees of biases, particularly in the performance
and detection bias domains. Given that outcome measures of clinical cure were not uniform, we were
unable to conduct a meta-analysis.
Conclusions: There is insufficient evidence for the use of inhaled antibiotic therapy as primary or adjuvant
treatment of VAP or VAT. Additional, better-powered randomized-controlled trials are needed to assess the
efficacy of inhaled antibiotic therapy for VAP and VAT.
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Background
Ventilator-associated pneumonia (VAP) is a healthcare-
associated infection (HAI) that affects 10–28 % of
patients receiving mechanical ventilation in the intensive
care unit (ICU) [1, 2]. Between 24 and 76 % of patients
with VAP die [1], with the mortality attributable to VAP
estimated at approximately 10 % [2]. VAP prevention
strategies include keeping the patient’s head of the bed
raised at 30–45°, use of chlorohexadine oral care, and
minimizing mechanical ventilation days through daily
readiness-to-wean trials [2]. Treatment of VAP includes
administering broad-spectrum intravenous antibiotics
targeted at different bacterial classes (e.g., gram-negative
bacteria, anaerobes). Adult infectious disease guidelines
published in 2005 recommend that efforts should be
made to shorten antibiotic courses for VAPs to limit
adverse effects [3]. Antibiotics used to treat these infec-
tions may cause systemic morbidity, including acute
kidney injury and C. difficile infections. Use of broad-
spectrum antibiotic therapy against gram-negative bacter-
ial causes of nosocomial ICU pneumonia have been
associated with increased bacterial antibiotic resistance
rates and selection for more virulent pathogens [4].
One potential therapeutic intervention for VAP and
VAT is aerosolized antibiotics. VAP treatment guidelines
published in 2005 do not address the use of inhaled anti-
biotics in the treatment or prevention of VAP and state
that “more data are needed on this type of therapy
before determining its value.” [3] Since publication of
this guideline, several groups have published clinical
trials assessing the use of inhaled antibiotics for the
prevention and treatment of VAP and VAT. Aerosolized
antibiotics may be efficacious in the treatment of
respiratory infections by delivering antibiotics directly to
the infection source (e.g., lungs), increasing antibiotic
concentration to overcome antimicrobial resistance
while limiting systemic absorption and decreasing drug
toxicity. Animal models testing aerosolized versus intra-
venous antibiotic therapy for treatment of Pseudomonas
aeruginosa demonstrated decreased bacterial load and
increased lung tissue antibiotic concentrations with use
of aerosolized antibiotics compared with intravenous
antibiotics [5, 6]. However, the role of aerosolized antibi-
otics in the treatment of VAP and VAT in humans
remains unclear. The objective of the current systematic
review is to assess, in patients with diagnosed VAP or
VAT, the efficacy and safety of using inhaled antibiotics
for treatment of VAP or VAT.
Method
Search strategy
Our systematic review’s study protocol (available upon
request) was developed using the guidelines set forth by
the Cochrane Collaboration [7] and the Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) [8]. In October 2014, we searched
three electronic databases (Pubmed, Cochrane Collab-
oration, and Web of Knowledge) for randomized
controlled trials that examine use of inhaled antibiotic
therapy in the treatment of VAP and VAT with the
technical support of an expert medical science librarian
at the University of Southern California (see Additional
file 1 for one search example).
Inclusion criteria
Included studies met all of the following criteria:
1. Patients: Study population was mechanically
ventilated patients diagnosed with VAP or VAT
2. Intervention: Use of inhaled antibiotics for treatment
of VAP or VAT compared to OR in addition to
intravenous antibiotics
3. Reported outcomes of a randomized controlled trial,
and
4. Outcome: Reported on some measurement of
clinical cure as an outcome (e.g. clinical pulmonary
infection score [CPIS])
Studies were excluded if they were written in a lan-
guage other than English, included patients on chronic
positive-pressure ventilation not hospitalized or studied
the use of inhaled antibiotics in patients who are not
intubated. Multiple published reports from a single
study were treated as a single data point.
Data extraction and analysis
Two authors (MS, BW) independently reviewed and
screened all studies for inclusion using a screening
tool to increase reproducibility. All study authors
reviewed studies when there were disagreements about
study inclusion and a consensus was reached. The
following information was extracted and documented
from studies that met inclusion criteria: study partici-
pant characteristics and setting, description of antibi-
otics studied including route of administration, doses,
frequencies, and duration of treatment, the study
period, length of follow up and outcomes such as
successful treatment.
The methodological quality of all studies that met
inclusion criteria was appraised using the Cochrane
Collaboration’s tool for assessing the risk of bias in the
reporting of clinical trials [7]. This tool rates the quality
of a study’s evidence by examining the potential bias in
selection, performance, detection, attrition, and report-
ing. Two authors (MS, BW) assessed the risk of bias for
each study that met inclusion criteria study and any
discrepancies were reconciled by consensus among
the authors.
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Results
Figure 1 details the study selection process. Our search
yielded 272 unduplicated articles, of which 40 were
excluded because they were not written in English and
did not meet inclusion criteria in review of the English
translation. Our review includes six studies describing
results of randomized controlled trials on the use of in-
haled antibiotics for the treatment of VAP or VAT [9–14].
Three hundred and five patients were enrolled across all
studies. One study each tested aerosolized tobramycin [9],
amikacin [11], colisthmethate sodium (CMS) [14], and
combined amikacin/ceftazidime [10], respectively; two
studies based aerosolized antibiotic choice upon culture
results at the treating physician’s discretion [12, 13]. Five
studies [9, 10, 12–14] utilized clinical measures of VAP
treatment success as a primary outcome measure, while
one study [11] included measures of treatment success as
a secondary outcome. Definition of the main outcome
Fig. 1 PRISMA diagram
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variable, successful treatment, varied widely across studies.
Two studies included rigorous and objective measures of
cure (e.g., Clinical Pulmonary Infection Score; range 0-12),
while others relied on less objective definitions (e.g.,
Favorable clinical outcome, as defined by the treating
physician or study team; Table 1). Third, the study quality
and risk for bias varied across the studies (Table 2). Length
of the study period varied from 7 to 36 months.
Overall, two studies [12, 13] found statistically signifi-
cant improvements in the primary clinical outcome
(clinical cure). Palmer and colleagues [12] reported that
aerosolized antibiotics resulted in significantly reduced
signs of respiratory infection and clinical pulmonary
infection score when compared to placebo score (mean
change ± SD = −1.42 ± 2.3; p = 0.02). With respect to their
secondary outcomes, this study reported that aerosolized
antibiotics resulted in lower white blood cell count at day
14 (in 103/mm3: AA: 9.2 ± 3.3 vs placebo: 14.9 ± 8.1;
p = 0.02), reduced bacterial resistance (AA: 0 % vs
placebo: 33 %; p < 0.01), reduced use of systemic anti-
biotics (AA: 47 % vs placebo: 70.8 %; p < 0.05) and
increased ventilator weaning (AA: 80 % vs placebo:
45 %; p < 0.05). A second study by Palmer [13] found
that compared with placebo, aerosolized antibiotics
significantly reduced clinical pulmonary infection
score (AA: 9.3 ± 2.7 to 5.3 ± 2.6 vs placebo: 8.0 ± 2.1
to 8.6 ± 2.6; p < 0.001).
Three studies [9, 11, 14] found no difference in clinical
cure rates when comparing intravenous antibiotics to
intravenous antibiotics combined with aerosolized anti-
biotics. In an adequately-powered study, Rattanaumpa-
wan and colleagues found no difference in favorable
clinical response between aerosolized colisthmethate
and aerosolized saline placebo, when used with intra-
venous antibiotics at the discretion of the treating
physician [14]. A small pilot study (n = 10) by Hallal et al.
[9] found that 100 % of VAP patients treated with
aerosolized tobramycin and intravenous β-lactam antibi-
otics had clinical resolution of VAP, compared to 60 % of
those receiving combined intravenous tobramycin and
β-lactam antibiotics; however, this result was not statisti-
cally significant difference due to low power. Niederman
et al. [11] randomized subjects to an investigational form
of amikacin (BAY41-6551) every 12 h, every 24 h or
placebo every 12 h. The primary outcome in the study
was the combination of tracheal aspirate amikacin max-
imum concentration ≥ 6400 μg/mL and ratio of area under
aspirate concentration-time curve to minimum inhibitory
concentration-time curve (0 –24 h) to minimum inhibi-
tory concentration ≥ 100 on day 1. Fifty percent and
16.7 % of their patients achieved the primary endpoint in
the every 12 h and every 24 h groups, respectively.
Secondary outcomes such as clinical cure rates were not
significantly different between the every 12 h, every 24 h
and placebo groups, respectively (p = 0.467). However, a
statistically significant difference in mean antibiotics per
patient per day was seen between the three groups, 0.9 in
the every 12 h, 1.3 in the every 24 h and 1.9 in the placebo
groups, respectively (p = 0.02 between the groups). In the
single study that compared aerosolized antibiotics alone to
intravenous antibiotics, Lu et al [10] found a 21.4 %
difference between nebulized and intravenous amikacin/
ceftazidime with respect to successful treatment (70 vs
55 %; p = 0.33), a 50 % reduction in treatment failure (15
vs 30 %; p = 0.26), and no difference superinfection with
other microorganisms (15 vs 15 %; p = 1.00) [10]. Overall,
no studies demonstrated that AA were associated with
poorer patient outcomes.
Risk of bias assessment (Table 2)
The risk of bias varied across the six studies evaluated in
this systematic review. All studies had low or unclear
risk of selection bias. Three studies [10, 11, 14] had high
risk of performance bias due to lack of blinding. Two
studies [10, 11] had high risk of detection bias due to
lack of blinding for those making the clinical cure
assessments, while one study [14] had unclear risk of
detection bias because they did not state who made the
assessments of clinical cure. Two studies [11, 12] had
high risk of attrition due to inability to conduct intention-
to-treat analysis [11] or high termination rate [12]. One
study [12] had high risk of reporting bias, as they did not
report clinical outcomes for all patients. Finally, two
studies [11, 12] had high risk of conflict of interest
bias given that they were industry sponsored, while
two additional studies [9, 13] did not discuss funding
sources or other conflicts of interest. Overall, only two
studies (Hallal [9], Palmer [13]) were assessed with
low or unclear risk of bias across all domains, while
Niederman [11] had a high risk of bias assessed across
five of six domains.
Discussion
Our systematic review found six articles that report that
aerosolized antibiotics may improve clinical cure for
VAP, particularly when combined with intravenous anti-
biotics. The strengths of the current systematic review
include use of the Cochran Collaboration/PRISMA [7, 8]
guidelines for reporting of systematic reviews and the
inclusion of only randomized controlled trials. All in-
cluded studies had a study arm that used either placebo
aerosolized medications or only systemic antibiotics for
comparison. Included studies used aerosolized antibi-
otics with a similar spectrum of antibacterial coverage.
Finally, the majority of the studies included had high
external validity in allowing treating clinicians’ discretion
to determine use of systemic antibiotics and other intensive
care measures.
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Table 1 Study Characteristics, Quality and Results, in Chronological Order









Hallal, et al, 2007 [9] N =10 Inhaled tobramycin or IV
tobramycin AND IV β-lactam
7 months 28 days Resolution of VAP 100 % of AA vs. 60 % of IV
patients had clinical resolution
of VAP. No p value reported.
Age: 23–72 (Mean age:
AA 52.6, IV 53.6)
Palmer et al, 2008 [12] N = 43 AA or saline placebo AND
systemic antibiotics (per
treating MD) was given for
14 days or until extubation
12 months 28 days Centers for Disease Control
National Nosocomial Infection




AA group had reduced signs
of respiratory infection [Centers
for Disease Control National
Nosocomial Infection Survey
and VAP (73.6 % to 35.7 %
vs. placebo: 75 % to 78.6 %)
and reduction in clinical
pulmonary infection score
(−1.42 vs. placebo: + 0.04),
(both p≤ .05).
Age: 19–92 (Mean age:
AA 62.3, placebo 62.7)
Rattanaumpawan et al, 2010 [14] N = 100 (Mean age:
AA 70.2, placebo 66.2)
Nebulized colistimethate
sodium or nebulized sterile
normal saline AND systemic
antibiotics per treating MD
38 months 28 days Favorable clinical outcome Favorable clinical outcome was
51.0 % in the AA group and 53.1 %
in the placebo group (p= 0.84).
Significant increase in favorable
microbiological outcome in AA vs.
placebo group (60.9 vs. 38.2 %;
p= 0.03)
Lu et al, 2011 [10] N = 40 patients Ages
43–77 (Mean age:
AA 58, IV 60)
Nebulized ceftazidime and
amikacin OR IV ceftazidime
and amikacin/ciprofloxacin.
36 month 28 days Successful treatment AA and IV groups performed
similar in terms of successful
treatment (70 vs. 55 %; p = 0.33).
Niederman et al, 2012 [11] N = 69 (Mean age: AA
q12h 56.1, AA q24h
62.8, or placebo 62.0)
Inhaled amikacin (BAY41-6551)
q12h, q24h, or placebo q12h
for 7–14 days, plus standard
IV antibiotics
13 months 31 days Clinical cure (secondary
study outcome)
Clinical cure achieved in 93.8 %
(AA q12h), 75 % (AA q24h) and
87.5 % (placebo; p = 0.467).
Palmer et al, 2014 [13] N = 43 (Mean age AA
57.5, placebo 60.6)
AA or saline placebo AND
systemic antibiotics (per
treating MD) was given for
14 days or until extubation
Does not state 14 days Clinical Pulmonary Infection
Score (CPIS)
CPIS score in AA significantly
reduced when compared to
placebo (Mean ± SE AA: 9.3 ± 2.7
to 5.3 ± 2.6 vs. placebo: 8.0 ± 23
to 8.6 ± 2.10; p = 0.0008)













Of the studies included, two reported statistically
significant clinical improvement when both nebulized
and intravenous antibiotics were delivered, compared to
intravenous antibiotics alone [12, 13]. Four studies
showed no statistical differences in clinical cure between
patients who received IV or aerosolized antibiotics [10]
or when nebulized antibiotics were added to intravenous
antibiotics [9, 11, 14]. Overall, only three studies [12–14]
had adequate power to detect a difference in clinical
cure rate; while the three remaining studies were pilot
studies [9, 10] or were powered for another clinical
outcome [11]. Only one study used aerosolized antibi-
otics without systemic antibiotics; this study showed a
clinically meaningful but non-statistically significant
21.4 % relative increase in successful treatment using
aerosolized antibiotics [10].
One potential explanation for the disparate results
involves the antibiotic nebulization technique. Achiev-
ing adequate treatment of any pulmonary infection
via inhaled antibiotics requires delivery of sufficient
antibiotics to the lungs. This involves adequate nebu-
lization of the antibiotics into appropriate particle size
for delivery in high concentrations. Previous research
demonstrates that certain types of nebulizers (e.g. jet
nebulizers) may be less efficient at antibiotic delivery
than other methods (e.g ultrasonic or vibrating plate
nebulizers) for patients on mechanical ventilation
[15]. Only three of the studies [11–13] included used
nebulizers with data that demonstrated that they had
adequate antibiotic delivery to the airway or lung. Of
the three papers using untested nebulizers, one used
a non-specified vibrating plate nebulizer [10], another
a Pari-Jet nebulizer [9] and the last did not specify
the nebulizer type [14]. Of all six studies, the two
studies that found positive results had appropriate
nebulizers [12, 13]. Thus, differences seen in efficacy
of inhaled antibiotics may be due to differential delivery of
antibiotics to the target tissue.
This systematic review has several limitations. First,
we excluded studies that were not randomized, con-
trolled trials written in English. By excluding ob-
servational studies, such as cohort and case-control
studies, we decreased the number of studies exam-
ined. This may have affected the external validity of
this systematic review by missing studies showing
significant changes that might affect the overall esti-
mate of effect sizes. Second, the primary study out-
come of the systematic review, clinical cure, was not
defined uniformly in each of the included studies.
Thus, there may be differential misclassification of
the study outcome leading to information bias that
might cause over- or underestimation of the effect
size. While all were randomized, controlled trials, two
[10, 14] were not blinded fully and relied on non-
blinded evaluation of clinical cure and two [11, 12]
were sponsored in part by pharmaceutical companies.
Unblinded studies may introduce bias by allowing the
outcome evaluators to misclassify study outcomes due
to treatment groups. Fourth, in five of the six studies,
all study participants were given intravenous antibi-
otics at the direction of the treating physician. There-
fore, we cannot determine the efficacy of using solely
aerosolized antibiotics, when compared to systemic
antibiotics in the treatment of VAP or VAT. Lastly,
publication bias may affect the current study’s conclu-
sions, as we may have missed studies that met inclu-
sion criteria but that were not published or studies
presented in abstract form that were submitted to
conferences but never published. However, that four
out of six studies had null findings suggests that there was
less publication bias specifically due to the absence of
statistically significant results.
Conclusion
This systematic review found insufficient evidence for
the use of inhaled antibiotic therapy as primary or
adjuvant treatment of VAP or VAT. Given the variations
in study protocols, antibiotics studied and vague defin-
ition of clinical cure as an outcome measure, additional,
adequately powered randomized-controlled trials with
strict definitions of outcome assessments and use of
previously validated nebulizer delivery methods for anti-
biotic administration are needed to assess the efficacy of
inhaled antibiotic therapy for VAP and VAT.
Table 2 Bias Assessment for Individual Studies
Study Selection Bias Performance Bias Detection Bias Attrition Bias Reporting Bias Conflict of Interest
Hallal, et al. (2007) [9] Low Low Low Low Low Unclear
Palmer et al. (2008) [12] Low Low Low High Low High
Rattanaumpawan et al. (2010) [14] Unclear High Unclear Low Low Low
Lu et al. (2011) [10] Unclear High High Low Low Low
Niederman et al. (2012) [11] Low High High High High High
Palmer et al. (2014) [13] Low Low Low Low Low Unclear
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